Tuesday, January 30, 2018

MabVax Under SEC Investigation

San Diego-based biotechnology developer MabVax Therapeutics Holdings reported today that the company is under investigation by the Securities and Exchange Commission (SEC). According to MabVax, it was informed that the SEC was conducting an investigation and examination, relating to the company's registration statements and amendments. Other details of the investigation were not announced. MabVax said it intends to "cooperate fully with the SEC's examination". MabVax is developing a monoclonal antibody targeted at treating cancer.